The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The role of covalent and non-covalent BTKIs in the MCL treatment landscape
Chan Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses the role of Bruton’s tyrosine kinase inhibitors (BTKIs) in treating mantle cell lymphoma (MCL). Currently, combinations involving covalent inhibitors like acalabrutinib and zanubrutinib are the standard of care for relapsed/refractory (R/R) MCL, with acalabrutinib also showing efficacy in the frontline setting according to the ECHO trial (NCT02972840). Ibrutinib has been withdrawn in the US due to negative results from the SHINE trial (NCT01776840). Additionally, pirtobrutinib, a non-covalent BTKI, is approved for patients with prior BTKI exposure. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
